Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Opal Rheumatology Ltd.

Status: Unknown

Conditions: Psoriatic Arthritis; Ankylosing Spondylitis; Rheumatoid Arthritis

Treatments: Biological: Biosimilar; Biological: Originator

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03470688

MSD biosimilars

Details and patient eligibility

About

An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a confirmed diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) who are being treated at a participating OPAL clinic.

Exclusion criteria

Trial design

5,000 participants in 2 patient groups

Originator

Description:

Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.

Treatment:

Biological: Originator

Biosimilar

Description:

Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.

Treatment:

Biological: Biosimilar